依普拉封对绝经后骨质疏松症骨密度及细胞因子的影响  

Effect of ipriflavone on bone mass density and cytokines in postmenopausal women with osteoporosis

作　　者：张咏言[1] 韩萍[1] 潘作东[1] 李莉[1] 李书琴[1] 

机构地区：[1]中国医科大学附属盛京医院内分泌科,沈阳110004

出　　处：《中国骨质疏松杂志》2008年第2期106-108,89,共4页Chinese Journal of Osteoporosis

摘　　要：目的观察激素替代物依普拉封对绝经后骨质疏松症的骨密度及细胞因子的影响。方法选择58例绝经后骨质疏松症患者,随机分成两组,治疗组32例应用依普拉封合用钙尔奇-D治疗6个月,对照组26例单独服用钙尔奇-D6个月,检测两组用药前后腰椎骨密度和骨代谢生化指标及细胞因子。结果治疗组结果表明骨吸收的指标:甲状旁腺素(PTH)、抗酒石酸盐酸性磷酸酶(TRAP),肿瘤坏死因子α(TNFα)和白细胞介素6(IL-6)均明显降低;骨形成/骨转换的指标:骨钙素(BGP)、Ⅰ型前胶原羧基端前肽(PICP)显著升高;骨重建刺激因子:胰岛素样生长因子-1(IGF-1),转化生长因子β1(TGF-β1)显著升高。结论依普拉封能明显的影响骨代谢:抑制骨吸收,促进骨形成,增加骨密度,能够有效地防治绝经后骨质疏松症,其作用机制与调节细胞因子有关。Objective To evaluate the effects of ipriflavone on the bone mineral density and cytokines in postmenopausal women with osteoporesis. Methods Fifty-eight postmenopausal women with osteoporesis were chosen and they were randomly divided in two groups. Thirty-two of them were given ipriflavone （200 mg, tid, po） ＋calcium compound（calcium 600 mg, vitamin D 125 IU, qd, po） and the other twenty-six given calcium compound （calcium 600 mg, vitamin D 125IU, qd, po） for 6 months. The bone mineral density, plasma biochemical parameters and TGF-β1, IGF-1, TNFα, IL-6 were measured before and after the treatment. Results Bone mineral density was significantly elevated after the treatment in ipriflavone group. Compared with those before treatment, the plasma concentrations of osteocalcin（BGP）, Type Ⅰ procollagen C-teminal peptide （PICP）, TGF-β1, IGF-1 were higher and the levels of plasma parathyroid hormone （PTH）, Tartrate resistant acid phosphatase （TRAP）, TNFα and IL-6 were lower after the treatment of ipriflavone. Conclusions Ipriflavone can inhibit the bone absorption, promote bone construction and increase the bone mineral density. Ipriflavone is an effective drug for prevention and treatment of osteoporosis in postmenopausal women. One of its mechanisms is associated with cytokines related to bone metabolism which were regulated by ipriflavone.

关 键 词：依普拉封 绝经期骨质疏松症 骨密度 骨钙素 细胞因子 

分 类 号：R965[医药卫生—药理学] R589.5[医药卫生—药学]